Creative Touch Permanent Makeup and Aesthetics

Caloric restriction triggers a conserved survival response that treats intentional dieting identically to famine – suppressing leptin by approximately 44%, elevating cortisol, and deprioritising non-essential tissue maintenance. For aesthetics clients, four distinct mechanisms are clinically relevant: cortisol simultaneously suppresses fibroblast procollagen transcription and accelerates collagen degradation; reduced protein intake widens the pre-existing glycine and proline shortfall for collagen synthesis; corticosterone suppresses Gas6 in dermal papilla niche cells, locking hair follicle stem cells in prolonged telogen quiescence; and subcutaneous atrophy reduces both skin mechanical support and the keratinocyte differentiation reserve needed for barrier repair. GLP-1 medications reproduce this entire biology pharmacologically, compounded by food preference shifts away from protein that clients are typically unaware of. Nutritional status assessment is a clinical prerequisite for collagen-stimulating and hair restoration treatments – not an optional recommendation.

Caloric restriction (CR) is defined as a sustained reduction in energy intake below the level required to maintain current body weight and metabolic function. The body does not distinguish between intentional dieting and genuine food scarcity – any consistent energy deficit triggers the same suite of conserved physiological responses designed to improve survival in conditions of famine. These responses include hormonal shifts that reduce energy expenditure, substrate prioritisation that routes available nutrients away from non-essential tissues, and suppression of tissue maintenance and regenerative programmes that consume energy without contributing to immediate survival. For aesthetics clients, the significance of these mechanisms is not hypothetical: the tissues most affected – dermal collagen, the hair follicle cycle, and the epidermal differentiation programme – are precisely the tissues that professional treatments aim to improve. ^[9]

The Hunger Hormone Cascade

The hormonal response to caloric restriction is rapid, consistent, and well-characterised. Leptin – produced by adipose cells in proportion to fat mass and energy availability – falls by approximately 44% during sustained energy restriction, and its decline is one of the primary drivers of the metabolic adaptation that follows. ^[8] As leptin falls, ghrelin – the primary hunger-signalling hormone – surges, activating mesolimbic reward pathways and intensifying cravings, particularly for energy-dense foods. ^[15] Simultaneously, resting metabolic rate adapts downward – research following the Minnesota Starvation Experiment protocol has confirmed reductions of approximately 10–15% beyond what the change in body mass alone would predict – a metabolic conservancy response that makes sustained restriction progressively harder. ^[13]

These are not signals of insufficient willpower – they are the predictable outputs of a survival system functioning exactly as it evolved to. The clinical relevance is that clients experiencing restriction, whether through deliberate dieting or GLP-1-mediated appetite suppression, are operating with a hormonal profile that actively deprioritises non-essential tissue maintenance. Skin, hair, and connective tissue repair sit below vital organ function, immune defence, and glucose homeostasis in that hierarchy.

The Cortisol Mechanism

Caloric restriction elevates cortisol output – not as a psychological response to dieting frustration, but as a direct physiological consequence of the energy deficit itself. A controlled trial by Tomiyama et al. (2010) demonstrated that three weeks of 1,200 kcal/day restriction significantly increased total urinary cortisol output compared to normal-eating controls, confirming the restriction-to-cortisol pathway in humans. ^[17]

Cortisol’s effect on dermal architecture is direct and well-evidenced. Oikarinen et al. (1983) demonstrated that cortisol selectively reduces procollagen mRNA concentration in cultured human skin fibroblasts – a transcriptional suppression of collagen type I synthesis at the gene expression level. ^[14] This was confirmed and extended by Chae et al. (2021), who showed in a reconstituted human skin model that cortisol inhibits collagen type I expression in dermal fibroblasts via glucocorticoid receptor-mediated suppression of TGF-β signalling – the growth factor pathway that is the primary driver of procollagen transcription. ^[1] Elevated autophagic degradation of existing collagen 1A1 under cortisol exposure has also been confirmed in human fibroblasts, indicating that elevated cortisol simultaneously suppresses new collagen synthesis and accelerates degradation of existing collagen. academic.oup.com

The practical implication is a double jeopardy for clients in active restriction: collagen output is suppressed at the transcriptional level whilst existing collagen is being degraded at an accelerated rate. Any professional treatment applied in this state is working against a biochemical headwind.

Clinical Pearl Elevated cortisol from caloric restriction is not a chronic stress response – it is a metabolic signal. It does not require the client to feel stressed or anxious for the fibroblast-suppressing effect to be active. Clients who are calmly and deliberately following a 1,200 kcal diet are producing this cortisol elevation as a direct consequence of their energy deficit.

Amino Acid Substrate Depletion

Even before the hormonal effects of caloric restriction become significant, the substrate supply for collagen synthesis declines as total protein intake falls. The collagen molecule requires glycine at every third position in its triple helix, and metabolic flux calculations demonstrate a structural shortfall of approximately 10g/day between endogenous glycine synthesis capacity and the demand for collagen production – a gap that exists in most adults even under adequate dietary conditions. ^[12] Under caloric restriction, where total protein intake is reduced, this gap widens. Glycine concentration has been directly shown to be the primary rate-limiting factor for collagen synthesis in fibroblast models – increasing glycine availability increases collagen output; reducing it suppresses it. ^[3]

Proline supply adds a second substrate constraint. Proline is synthesised endogenously from glutamine via the ALDH18A1 enzyme, but this pathway is rate-limited by enzyme capacity and dependent on glutamine availability. Under caloric restriction, glutamine is consumed by rapidly dividing immune cells and enterocytes – uses that take priority over fibroblast proline synthesis. The consequence is that proline availability in the dermis declines through the substrate supply chain even when dietary protein is nominally present, because the upstream precursor is being competed for by higher-priority demands. ^[7]

This substrate depletion operates independently of the cortisol mechanism – the two effects are additive. A client in active caloric restriction may be experiencing suppressed procollagen transcription (cortisol), reduced glycine availability (protein restriction), and reduced proline precursor supply (glutamine competition) simultaneously, each constraining collagen output through a different point in the synthesis pathway.

Lean Mass Loss and Keratin Substrate

Caloric restriction consistently results in loss of lean tissue alongside fat. This is not unique to pharmaceutical weight loss – all forms of sustained energy deficit produce lean mass loss as a proportion of total weight loss, with approximately 25% of weight lost typically comprising lean tissue under controlled conditions. ^[11] That lean mass loss depletes the cysteine and glycine pools available for hard keratin synthesis in the hair follicle, since muscle protein is a primary reservoir for circulating amino acids during restriction. Hair shaft tensile strength and diameter are downstream of the cysteine availability that determines disulfide cross-link density in trichocyte keratins – and the loss of that substrate supply is reflected in the shaft quality changes that commonly accompany significant weight loss.

Hair Follicle Arrest: The Corticosterone-Gas6 Mechanism

The most precisely characterised mechanism by which caloric restriction-induced cortisol elevation affects hair is not nutritional depletion – it is direct hormonal signalling to the hair follicle niche. Choi et al. (2021) published landmark research in Nature identifying the molecular pathway: corticosterone (the cortisol equivalent) acts on dermal papilla (DP) cells in the follicle to suppress expression of Growth Arrest Specific 6 (Gas6) – a secreted signalling protein that is the primary activating signal for hair follicle stem cells (HFSCs). ^[2]

When corticosterone suppresses Gas6 in the DP, HFSCs receive no activation signal and remain in prolonged quiescence – extending the telogen resting phase and delaying anagen entry. Crucially, corticosterone does not act on HFSCs directly; it acts on the niche cells that regulate them, making the effect conditional on the dermal environment rather than the stem cell’s intrinsic capacity. When Gas6 is restored – either by removing the corticosterone source or by direct Gas6 overexpression via AAV injection – HFSC activation resumes and hair cycle progression normalises, even in a high-corticosterone environment. ^[2] This is not a theoretical pathway – it is a confirmed, reversible regulatory mechanism operating through a precisely identified molecular axis: corticosterone → DP glucocorticoid receptor → Gas6 suppression → HFSC quiescence. Telogen effluvium following rapid weight loss is the clinical expression of this pathway operating in human follicles. ^[6]

The Skin Barrier: Volume Loss and Differentiation Suppression

The relationship between caloric restriction and skin barrier function is more nuanced than a simple breakdown narrative. Li et al. (2024) demonstrated in a controlled murine model that short-term CR (2 weeks at 70% of ad libitum intake) did not significantly alter trans-epidermal water loss or the mRNA expression of barrier proteins including filaggrin, loricrin, involucrin, K10, or K14 in healthy skin. ^[16] Under short-term conditions in healthy skin, caloric restriction does not appear to directly disrupt the epidermal barrier – trans-epidermal water loss and barrier protein mRNA expression remain intact.. However, the same study found two effects of direct clinical relevance: first, CR produced significant subcutaneous tissue atrophy – a measurable reduction in the thickness and adipocyte volume of the hypodermis – which affects the mechanical support and surface appearance of the skin independently of barrier function; and second, CR inhibited both keratinocyte proliferation and differentiation under pathological conditions (including wound-like IMQ challenge), with K10, filaggrin, loricrin, and involucrin expression all significantly attenuated. The barrier, therefore, may be intact at rest under short-term restriction but is operating with a reduced regenerative reserve – a compromised capacity to mount the differentiation programme that barrier repair requires when the skin faces challenge. For clients undergoing procedures that deliberately disrupt the barrier to stimulate repair, this distinction is clinically significant.

The GLP-1 Context: Restriction Amplified

^[4] A separate study of 69 GLP-1 users found 98.6% deficient in vitamin D and 88.4% deficient in iron alongside the same protein inadequacy pattern – with only 43% of participants reaching the minimum 1.2g/kg threshold and just 10% achieving 1.6g/kg. ^[5]

The reason for this inadequacy is not simply reduced appetite – it is a documented shift in food preferences. Linge, Birkenfeld and Neeland (2024) noted in a focused review of GLP-1 trial data published in Circulation that food preference shifts away from protein-rich foods – including dairy and meat – contribute to inadequate protein intake during treatment, compounding the effect of overall appetite suppression. ^[10] This creates a particular challenge: patients need more protein per calorie consumed to preserve lean tissue during active weight loss, but the medication’s effect on food preferences actively works against meeting that requirement.

The tissue cost of this is measurable. In the SURMOUNT-1 DXA substudy, approximately 25% of total weight lost with tirzepatide comprised lean mass – a proportion consistent with standard weight loss ratios but representing an absolute lean mass loss of approximately 5–7kg over 72 weeks. ^[11] In the STEP-1 semaglutide body composition substudy, the lean mass proportion was substantially higher at approximately 40% of total weight lost – a discrepancy between agents that remains unexplained and may reflect differences in GIP receptor activity. ^[18] This lean mass depletion reduces the amino acid reservoirs that skin and hair synthesis draw from, operating in parallel with the cortisol-mediated suppression of fibroblast procollagen transcription described above.

The Optimality Reframe

The standard nutritional framing of caloric restriction addresses it primarily as a clinical risk factor for deficiency disease in populations with inadequate intake. That framing systematically understates its relevance for aesthetics clients in the optimality context – the question is not whether restriction causes frank malnutrition, but whether it reduces the resource availability for skin and hair tissue maintenance below the threshold required for optimal output from professional treatments. The cortisol, amino acid substrate, lean mass, and Gas6 mechanisms described above are active across a wide range of restriction intensities, not only at the extremes. A client consuming 1,200 kcal/day is experiencing measurable cortisol elevation, measurable leptin suppression, measurable procollagen transcription suppression, and measurable substrate depletion – none of which require clinical malnutrition to be functionally significant for treatment outcomes. Addressing nutritional status as a prerequisite for, rather than an adjunct to, professional treatment is the clinical stance the evidence supports.